metricas
covid
Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Estudio de la replicación del virus de la hepatitis B e infección por otros vi...
Journal Information
Vol. 25. Issue 5.
Pages 295-298 (January 2002)
Share
Share
Download PDF
More article options
Vol. 25. Issue 5.
Pages 295-298 (January 2002)
Full text access
Estudio de la replicación del virus de la hepatitis B e infección por otros virus hepatotropos en pacientes con infección crónica por el virus B
Study of hepatitis B virus replication and infection by other hepatitis viruses in patients with chronic hepatitis B virus infection
Visits
9216
M. Buti**
Corresponding author
mbuti@hg.vhebron.es

Correspondencia: Servicio de Hepatología. Hospital General Universitario Vall d’Hebron. Paseo Vall d’Hebron, 117. 08035 Barcelona.
, A. Valdés, R. Esteban, J. Guardia
Servicio de Hepatología. Laboratorio de Bioquímica
X. Costa*, M. Cotrina*, F. Rodríguez Frías*, R. Jardí*
* Hospital General Universitario Vall d’Hebron. Barcelona
This item has received
Article information
Resumen
Fundamento

Estudiar la replicación del virus de la hepatitis B (VHB) en una serie de pacientes con infección por el VHB y analizar la frecuencia de infección asociada por los virus de la hepatitis C (VHC) y D (VHD).

Pacientes y Método

Se han estudiado en una muestra de suero perteneciente a 463 pacientes con infección crónica por el VHB los marcadores serológicos del VHB, VHC y VHD, los valores de transaminasas y el ADN del VHB.

Resultados

Trescientos noventa y seis (85,5%) fueron catalogados como hepatitis B, 33 (7,1%) como hepatitis B y C, 17 (3,6%) como hepatitis B y D y 17 (3,6%) como hepatitis B, C y D. El 67% de los pacientes con hepatitis B eran portadores asintomáticos del HBsAg, y el 33%, hepatitis crónicas B. El ADN del VHB se identificó en el 27,7% de las hepatitis B, en el 24% de las hepatitis B y C, en el 11,7% de las hepatitis B y D, y en el 29,4% de las hepatitis B, C y D. El ADN del VHB era positivo y las transaminasas estaban elevadas en el 63% de los casos HBeAg positivo y solamente en el 16% de los anti-HBe, por lo que éstos se consideraron candidatos a tratamiento antiviral.

Conclusiones

En nuestro medio, la mayoría de los pacientes con infección por el VHB son portadores asintómaticos del HBsAg. En el 22% de los casos se detecta replicación viral y presentan valores de ALT elevados; por tanto, son candidatos a tratamiento antiviral. Entre el 3,6 y el 7,1% de las hepatitis B presentan coinfección por el VHC, VHD o ambos, sin que se observen diferencias significativas en la replicación del VHB entre los distintos grupos.

Abstract
Aim

To study hepatitis B virus (HBV) replication in a series of patients with HBV infection and to analyze the frequency of associated hepatitis C virus (HCV) and hepatitis D (HDV) infection.

Patients and Method

Serological markers of HBV, HCV and HDV, transaminase values and HBV DNA were studied in serum samples from 463 patients with chronic HBV infection.

Results

Three hundred ninety-six (85.5%) were classified as hepatitis B, 33 (7.1%) as hepatitis B and C, 17 (3.6%) as hepatitis B and D and 17 (3.6%) as hepatitis B, C and D. Sixty-seven percent of patients with hepatitis B and 33% of those with chronic hepatitis B were asymptomatic HBsAg carriers. HVB DNA was identified in 27.7% of patients with hepatitis B, in 24% of those with hepatitis B and C, in 11.7% of those with hepatitis B and D and in 29.4% of those with hepatitis B, C and D. HBV DNA and elevated transaminase levels were found in 63% of HBeAg-positive patients and in only 16% of those who were anti-HBe-positive. These latter were considered candidates for antiviral treatment.

Conclusions

In our environment, most patients with HBV infection are asymptomatic HBsAg carriers. Viral replication and elevated alanine aminotransferase levels were found in 22% of the patients. Consequently, these patients are candidates for antiviral treatment. Between 3.6% and 7.1% of patients with hepatitis B presented coinfection with HCV or HDV, or both. No significant differences were found in HBV replication among the different groups.

Full text is only aviable in PDF
Bibliogrífia
[1.]
M.J. Alter, E.E. Mast.
The epidemiology of viral hepatitis in the United States.
Gastroenterol Clin North Am, 23 (1994), pp. 437-455
[2.]
M. Kane.
Global programme for control of hepatitis B infection.
Vaccine, 13 (1995), pp. S47-S49
[3.]
A.S. Look.
Hepatitis B infection: pathogenesis and management.
J Hepatol, 32 (2000), pp. 89-97
[4.]
M.L. William.
Hepatitis B virus infection.
N Engl J Med, 337 (1997), pp. 1733-1745
[5.]
J.H. Hoofnagle.
Chronic hepatitis B.
N Engl J Med, 323 (1990), pp. 337-339
[6.]
L. Salleras, P. Plans, J. Vidal, A. Domínguez-García, E. Navas, L. Urbiztondo, et al.
Serological evaluation of universal vaccination programme of pre-adolescents in Catalonia (Spain).
Vacunas, 1 (2000), pp. 3-6
[7.]
T. Stroffolini, A. Mele, M.E. Tosti, G. Gallo, E. Balocchini, P. Ragni, et al.
The impact of the hepatitis B mass immunisation campaing on the incidence and risk factors of acute hepatitis B in Italy.
J Hepatol, 33 (2000), pp. 980-985
[8.]
J. Dienstang, R.P. Perrillo, E.R. Schiff, M. Bartholomew, C. Vicary, M. Rubin.
A preliminary study of lamivudine for chronic hepatitis B infection.
N Engl J Med, 333 (1995), pp. 1657-1661
[9.]
C.L. Lai, R.N. Chien, N.W. Leung, T.T. Chang, R. Crian, D.I. Tai.
A one-year of lamivudine for chronic hepatitis B. Asia Lamivudine Study Group.
N Engl J Med, 339 (1998), pp. 61-68
[10.]
F. Zoulin, C. Trepo.
Drug therapy for chronic hepatitis B: antiviral efficay and influence of hepatitis B virus polymerase mutations on the outcome of therapy.
J Hepatol, 29 (1998), pp. 151-168
[11.]
F. Rodriguez, M. Buti, R. Jardi, M. Cotrina, L. Viladomiu, R. Esteban, et al.
Hepatitis B virus infection. Precore mutants and its relation to viral genotypes.
Hepatology, 22 (1995), pp. 1461-1467
[12.]
Y.F. Liaw.
Role of hepatitis C virus in dual and triple hepatitis virus infection.
Hepatology, 22 (1995), pp. 1101-1107
[13.]
J. Crespo, J.L. Lozano, B. Carte, B. Heras, F. Cruz, F. Pons Romero.
Viral replication in patients with concomitant hepatitis B and C virus infections.
Eur J Clin Microbiol Infect Dis, 16 (1997), pp. 445-451
[14.]
G.B. Gaeta, T. Stroffolini, M. Chiaramonte, T. Ascione, G. Stornaiuolo, S. Lobello, et al.
Chronic hepatitis D: a vanishing disease?.
An Italian Multicenter Study. Hepatology, 32 (2000), pp. 824-827
[15.]
C.A. Navascués, M. Rodríguez, N.G. Sotorrio, P. Sala, A. Linares, A. Suárez, et al.
Epidemiology of hepatitis D infection: changes in the last 14 years.
Am J Gastroenterol, 11 (1995), pp. 1981-1984
[16.]
M. Buti, R. Esteban, R. Jardí, H. Allende, J.M. Baselga, J. Guardia.
Epidemiology of Delta infection in Spain.
J Med Virol, 26 (1988), pp. 327-332
[17.]
E. Sagnelli, N. Coppola, C. Scolastico, P. Filippini, T. Santantonio, T. Stroffolini, et al.
Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis.
Hepatology, 32 (2000), pp. 1106-1110
[18.]
A. Lok, J. Heathcote, J. Hoofnagle.
Management of hepatitis B: 2000-Summary of a Workshop.
Gastroenterology, 120 (2001), pp. 1828-1853
[19.]
CDC Update.
Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B, and other blood borne pathogens in health-care settings.
MMWR, 36 (1988), pp. 377-388
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos